Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
Journal
Vaccine
Journal Volume
22
Journal Issue
29-30
Pages
3993-4001
Date Issued
2004
Author(s)
Abstract
Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy. ? 2004 Elsevier Ltd. All rights reserved.
SDGs
Other Subjects
calreticulin; cancer vaccine; CD8 antigen; gamma interferon; tumor antigen; vaccinia vaccine; animal cell; animal experiment; antineoplastic activity; article; controlled study; cytokine release; drug effect; drug efficacy; drug potency; drug targeting; lung tumor; mouse; nonhuman; priority journal; T lymphocyte; Wart virus
Publisher
Elsevier BV
Type
journal article